Q-omics provides the consensus-scored TNS4 profile across patient tissues and cancer cell-line models. TNS4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TNS4 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TNS4 RNA expression shows 14,506 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, COAD, and THYM as cancer lineages where TNS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNS4 survival associations across molecular data types. TNS4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNS4 RNA expression–survival associations across cancer types. High TNS4 expression shows unfavorable associations in LUAD, MESO, KIRC, GBM and OV, but favorable associations in UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TNS4 RNA expression.
This table summarizes TNS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNS4 shows lower tumor expression in KIRC and KIRP and higher tumor expression in COAD, HNSC, LUSC and LUAD. The COAD box plot shows higher TNS4 RNA expression in tumor versus normal tissue (log2 FC = +3.485, t-test p < 0.001).
This table shows molecular features associated with TNS4 in patient tissues and cancer cell lines. In patient samples, TNS4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and URINARY_TRACT.
